Martin Devenport

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder”.

CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder

Cell Metabolism(2022)10.1016/j.cmet.2022.07.005

N/A

1.8DataRank · unranked

68 citations

Mingyue Liu, Jifeng Zhang, Nicholas K. Brown, Peng Zhang, Yan Zhang +11 more

First-in-human phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3159

N/A

0DataRank · unranked

1 citations

Søren M. Bentzen, Martin Devenport, Yang Liu, Pan Zheng, Christian Rolfo

Treatment with Soluble CD24 Attenuates COVID-19-Associated Systemic Immunopathology

medRxiv(2021)10.1101/2021.08.18.21262258

N/A

0DataRank · unranked

3 citations

Carter Allen, Anna E. Vilgelm, Brian Riesenberg, Kevin P. Weller, Kelsi Reynolds +25 more

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

Journal of Clinical Investigation(2022)10.1172/jci150846

N/A

0DataRank · unranked

141 citations

Yan Liu, Mingyue Liu, Xuexiang Du, Martin Devenport, Pan Zheng +3 more

A novel aptamer-based small RNA delivery platform and its application to cancer therapy

Genes & Diseases(2022)10.1016/j.gendis.2022.05.004

N/A

0DataRank · unranked

11 citations

Peng Zhang, Christopher M. Bailey, Yin Wang, Wannaporn Ittiprasert, Martin Devenport +3 more

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

Signal Transduction and Targeted Therapy(2022)10.1038/s41392-022-01030-x

N/A

0DataRank · unranked

14 citations

Xu Wang, Xuexiang Du, Yan Zhang, Chunxia Ai, Siwen Hu‐Lieskovan +5 more

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Cancers(2020)10.3390/cancers12020284

N/A

0DataRank · unranked

14 citations

Xinxin Xiong, Christian Rolfo, Xuexiang Du, Yan Zhang, Han Yang +6 more

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy

Science Translational Medicine(2023)10.1126/scitranslmed.abm5663

N/A

0DataRank · unranked

18 citations

Xu Wang, Xuexiang Du, Wei Wu, Yan Zhang, Peng Zhang +8 more